Beyond lipid-lowering: effects of statins on endothelial nitric oxide (Q35084723)

6 August 2017

1 reference

title

Beyond lipid-lowering: effects of statins on endothelial nitric oxide (English)

1 reference

6 August 2017

0 references

Ulrich Laufs

1

1 reference

6 August 2017

18 February 2003

1 reference

European Journal of Clinical Pharmacology

6 August 2017

1 reference

6 August 2017

58

1 reference

6 August 2017

719-731

1 reference

6 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-002-0556-0

6 August 2017

0 references

cites work

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Current concepts of the pathogenesis of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

21 January 2018

NO: the primary EDRF.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide-an endothelial cell survival factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide: an endogenous modulator of leukocyte adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Hypertension in mice lacking the gene for endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Statins and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Improvement of coronary vasodilatation capacity through single LDL apheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Inhibition of LOX-1 by statins may relate to upregulation of eNOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Direct effects of statins on cells primarily involved in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Rho GTPases and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Direct vascular effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Inactivation of endothelial derived relaxing factor by oxidized lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Oxygen reduction by nitric-oxide synthases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Cellular antioxidant effects of atorvastatin in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Dynamic activation of endothelial nitric oxide synthase by Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Withdrawal of statins increases event rates in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Beyond lipids - the role of the endothelium in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-002-0556-0

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

21 January 2018

1 reference

12 December 2020

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

12 December 2020

Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration

1 reference

12 December 2020

Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?

1 reference

12 December 2020

Contribution of nitric oxide to metabolic coronary vasodilation in the human heart

1 reference

12 December 2020

Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells

1 reference

12 December 2020

Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins

1 reference

12 December 2020

Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA

1 reference

12 December 2020

Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

12 December 2020

Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia

1 reference

12 December 2020

Restoring vascular nitric oxide formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease

1 reference

12 December 2020

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

1 reference

12 December 2020

Peroxynitrite and atherosclerosis

1 reference

12 December 2020

Out, damned dot: studies of the NADPH oxidase in atherosclerosis

1 reference

12 December 2020

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

12 December 2020

Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs

1 reference

12 December 2020

Selective impairment of nitric oxide dependent vasodilation in young adults with hypercholesterolaemia

1 reference

12 December 2020

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts

1 reference

12 December 2020

Targeting Rho in cardiovascular disease

1 reference

12 December 2020

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

1 reference

12 December 2020

Small, dense low-density lipoprotein particles and coronary heart disease risk: A clear association with uncertain implications

1 reference

12 December 2020

Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo

1 reference

12 December 2020

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

12 December 2020

Treatment of oesophageal rupture

1 reference

12 December 2020

Statin-stimulated nitric oxide release from endothelium

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium

1 reference

12 December 2020

Endothelium and acute coronary syndromes

1 reference

12 December 2020

Nitric oxide regulates monocyte chemotactic protein-1

1 reference

12 December 2020

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

12 December 2020

Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice

1 reference

12 December 2020

The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis

1 reference

12 December 2020

More than cholesterol: the complexity of coronary artery disease

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

12 December 2020

10.1007/S00228-002-0556-0

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12634978